SVF
Level D· Preclinical EvidenceAnimal Study

Increased efficacy of adipose-derived mesenchymal stem cells transduced with klotho in differentiation and maturation of oligodendrocytes in a mouse model of experimental autoimmune encephalomyelitis.

Rezapour Kalkhoran M., Maleki N., Rahbarizadeh F., Allameh A.

Animal Study on Neuroinflammation, Immune Modulation, Autoimmune Research, published in J Neuropathol Exp Neurol (2026) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
J Neuropathol Exp Neurol (2026)
Country
England
Reported sample size
—
PMID
40971616
DOI
10.1093/jnen/nlaf095

Abstract (original English)

Current therapies for multiple sclerosis (MS) exert immunomodulatory effects but do not directly repair central nervous system (CNS) damage. Mesenchymal stem cells (MSCs) have emerged as a promising therapeutic strategy for MS, as they have been shown to promote myelin repair. Genetic modifications of MSCs have been reported to enhance their therapeutic efficiency in neurodegenerative diseases. This study aimed to investigate the therapeutic potential of MSCs engineered with secreted klotho (s-KL) in enhancing remyelination by mature oligodendrocytes in an experimental autoimmune encephalomyelitis (EAE) model in mice. The results showed that MSCs carrying s-KL alleviated clinical signs and reduced inflammation and demyelination in the CNS more significantly than MSCs. Compared to MSCs, s-KL MSCs also exhibited an enhanced capacity for differentiation and maturation of oligodendrocytes, as demonstrated by increased mRNA and protein expression of Olig2 and Nogo-A in the CNS of mice with EAE. These findings indicate that overexpression of s-KL enhances the therapeutic potential of MSCs to induce remyelination and may represent a novel approach to improve the efficacy of stem cell-based therapy in MS.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence comes from animal or laboratory studies and has not been confirmed in humans.

How we grade evidence
AnimalsEncephalomyelitis, Autoimmune, ExperimentalMiceMesenchymal Stem CellsCell DifferentiationOligodendrogliaMesenchymal Stem Cell TransplantationMice, Inbred C57BLKlotho ProteinsGlucuronidase
Systemic / IVNeuroinflammationImmune ModulationAutoimmune Research
View on PubMedDOI

Related research